Φορτώνει......
Allogeneic hematopoietic cell transplantation for myelofibrosis in the era of JAK inhibitors
The discovery of JAK2617F mutation paved the way for the development of small molecule inhibitors of JAK1/2 resulting in first approved JAK1/2 inhibitor, ruxolitinib, for the treatment of patients with myelofibrosis (MF). Although JAK1/2 inhibitor therapy is effective in decreasing the burden of sym...
Αποθηκεύτηκε σε:
| Τόπος έκδοσης: | Blood |
|---|---|
| Κύριοι συγγραφείς: | , , |
| Μορφή: | Artigo |
| Γλώσσα: | Inglês |
| Έκδοση: |
American Society of Hematology
2012
|
| Θέματα: | |
| Διαθέσιμο Online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5800543/ https://ncbi.nlm.nih.gov/pubmed/22700718 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2012-05-399048 |
| Ετικέτες: |
Προσθήκη ετικέτας
Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!
|